Danish biotech companies launch IPOs
The biotech company Orphazyme A/S has just been listed at Nasdaq Copenhagen, and Zealand Pharma A/S was listed on the Nasdaq Global Select Market in the United States in August. Plesner assisted both companies with their IPOs and thus reinforces its position as Denmark's leading advisor as regards initial public offerings of biotech companies in Denmark and abroad.
Orphazyme listed in Copenhagen
Orphazyme was admitted to trading and official listing on Nasdaq Copenhagen on 16 November 2017. The IPO will raise DKK 600m in new capital for Orphazyme. The new capital will be used for financing of further product development. The offering price for Orphazyme's shares in connection with the IPO was DKK 80 per share, which gives the company a total value of DKK 1.6bn.
Orphazyme, which was founded in 2009, performs research into pharmaceutical products for the treatment of rare diseases. SEB, Vækstfonden (The Danish Growth Fund), BankInvest, Handelsbanken and Spar Nord are among the new investors that had all undertaken in advance to purchase some of the shares in Orphazyme.
Zealand Pharma listed in the United States
In August 2017, the biotech company Zealand commenced its initial public offering of American Depositary Shares on the Nasdaq Global Select Market in the United States. The IPO increased the company's access to capital from US investors and provided financing for Zealand Pharma's continued clinical development of important product candidates.
Zealand Pharma was listed at Nasdaq Copenhagen in Denmark in 2010. In the autumn of 2016, the company further issued new shares corresponding to DKK 143m in an accelerated book-building process. Plesner advised Zealand Pharma on both occasions.
Leading advisor as regards biotech
Plesner is Denmark's leading advisor as regards IPOs and other capital market transactions with respect to biotech, both in Danish and cross-border transactions. By the two current IPOs, Plesner has again increased its extensive experience in the area.
Plesner previously advised in connection with, for instance, the IPOs relating to Zealand Pharma A/S in Denmark, Nuevolution A/S in Sweden and Forward Pharma A/S at Nasdaq New York.